Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study

AIMS: To examine the efficacy and safety of once‐weekly dulaglutide 0.75 mg monotherapy compared with once‐daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks. METHODS: We conducted a phase III, randomized, 52‐week (26‐week primary endpoint), active‐ and placebo‐con...

Descripción completa

Detalles Bibliográficos
Autores principales: Odawara, M., Miyagawa, J., Iwamoto, N., Takita, Y., Imaoka, T., Takamura, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064615/
https://www.ncbi.nlm.nih.gov/pubmed/26661514
http://dx.doi.org/10.1111/dom.12602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064615/
https://www.ncbi.nlm.nih.gov/pubmed/26661514
http://dx.doi.org/10.1111/dom.12602

Ejemplares similares